B+
Bull case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
CTNM
Contineum TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
BMY's 60 mg Phase 3 IPF success supports the LPA1 mechanism, while CTNM retains a funded Phase 2 opportunity: it reported $236.6 million of cash, equivalents and marketable securities at June 30 and projected runway through mid-2029. These do not establish PIPE-791 efficacy.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -55.0.
What can break
BMY's mixed dose results complicate class read-through, and a competitor's success does not validate PIPE-791 specifically. Source: https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Phase-3-ALOFT-IPF-Trial-Evaluating-Admilparant-in-Adults-with-Idiopathic-Pulmonary-Fibrosis-Met-Primary-Endpoint/default.aspx
Momentum
3
Value
41
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.00 · Bull $12.00 · Bear $4.00Analysis 2026-10-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $22.14
Why
Momentum3 · Δ7d -0.8
Value41 · Δ7d -0.1
Sentiment45 · Δ7d -55.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -55.0.
Contradictions & invalidation
- • BMY's mixed dose results complicate class read-through, and a competitor's success does not validate PIPE-791 specifically. Source: https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Phase-3-ALOFT-IPF-Trial-Evaluating-Admilparant-in-Adults-with-Idiopathic-Pulmonary-Fibrosis-Met-Primary-Endpoint/default.aspx
- • PIPE-791 IPF efficacy, safety and trial timing remain unproven; CTNM is concentrated in an early-stage lead asset. [#SEC-8K-2026-07-30]
- • MOONLIGHT-1 missed its primary endpoint, leaving J&J's next steps uncertain.
Catalyst clock
2027-03-31
Partner decision after MOONLIGHT-1 miss
Lead driver: Sentiment · See AI snapshot
Momentum
3
8% active weight
Current posture
7d trendFlat
Δ7d
-0.8
Δ21d
-11.9
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
45
45% active weight
Current posture
7d trendSoftening
Δ7d
-55.0
Δ21d
-23.5
Why this grade
Composite grade F. Momentum 2.5 / Value 40.6 / Sentiment 44.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-18. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$312.63M
Beta
-
Shares Out
37.62M
P/E (TTM) · Derived
-3.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.16
Rev YoY
-100.0%
EPS YoY
-34.7%
Gross Margin
+99.6%
Op Margin
-
Net Debt
-$254.65M
Current Ratio
37.17
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data